Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, recently shared key findings with Steve Darling from Proactive following the company's presentations at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems in Rome. The presentations detailed the eutectic formation of cyclobenzaprine HCl and mannitol, highlighting its stability and rapid dissolution, allowing for efficient transmucosal delivery of cyclobenzaprine into the bloodstream. This innovative formulation protects the drug from interacting with the basifying agent needed for absorption, offering a more effective delivery system. Dr. Lederman emphasized the ongoing unmet need for fibromyalgia treatments, with many patients unsatisfied with current options. Tonix's lead candidate, TNX-102 SL, has shown significant potential as a once-daily bedtime treatment that could provide broad-spectrum symptom relief for fibromyalgia patients. With promising results from two Phase 3 studies, TNX-102 SL is positioned to become the first new treatment for fibromyalgia in 15 years, offering hope to millions of patients seeking better management of their symptoms. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Fibromyalgia #TNX102SL #FDAApproval #DrugDevelopment #PharmaceuticalInnovation #BiotechNews #ClinicalTrials #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews